Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation
Executive Summary
An undisclosed G-protein coupled receptor playing a role in inflammatory disease will be the focus of a drug pact between Heptares and PeptiDream.
You may also be interested in...
Biopharma Quarterly Deal-Making Statistics, Q2 2017
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.
Allergan 'Unusual Suspect' But Pipeline 'Hunger' A Perfect Match For Heptares
With Scrip still reeling from the news earlier this week that Pfizer and Allergan have called off their $160bn mega-merger, news broke that former darling of the UK biotech scene Heptares, now a wholly-owned subsidiary and the 'R&D engine' of Japanese company Sosei Group Corp., has secured a notable licensing deal with Allergan. Scrip caught up with Heptares CEO Malcolm Weir to get his take on the fall of PfizerGan (PfAllergan?), and of course the small matter of securing a partnership deal worth up to $3.34bn plus potential royalties.
Pfizer Takes 3% Stake In Sosei On Back Of Heptares GPCR Deal
Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.